JP2013532971A5 - - Google Patents

Download PDF

Info

Publication number
JP2013532971A5
JP2013532971A5 JP2013515914A JP2013515914A JP2013532971A5 JP 2013532971 A5 JP2013532971 A5 JP 2013532971A5 JP 2013515914 A JP2013515914 A JP 2013515914A JP 2013515914 A JP2013515914 A JP 2013515914A JP 2013532971 A5 JP2013532971 A5 JP 2013532971A5
Authority
JP
Japan
Prior art keywords
antigen
homodimeric protein
protein according
nucleic acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013515914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013532971A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/060628 external-priority patent/WO2011161244A1/en
Publication of JP2013532971A publication Critical patent/JP2013532971A/ja
Publication of JP2013532971A5 publication Critical patent/JP2013532971A5/ja
Withdrawn legal-status Critical Current

Links

JP2013515914A 2010-06-25 2011-06-24 ホモ二量体タンパク質コンストラクト Withdrawn JP2013532971A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35851310P 2010-06-25 2010-06-25
EP10167291 2010-06-25
EP10167291.3 2010-06-25
US61/358,513 2010-06-25
PCT/EP2011/060628 WO2011161244A1 (en) 2010-06-25 2011-06-24 Homodimeric protein constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016154365A Division JP6538622B2 (ja) 2010-06-25 2016-08-05 ホモ二量体タンパク質コンストラクト

Publications (2)

Publication Number Publication Date
JP2013532971A JP2013532971A (ja) 2013-08-22
JP2013532971A5 true JP2013532971A5 (cg-RX-API-DMAC7.html) 2014-08-14

Family

ID=42983487

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013515914A Withdrawn JP2013532971A (ja) 2010-06-25 2011-06-24 ホモ二量体タンパク質コンストラクト
JP2016154365A Active JP6538622B2 (ja) 2010-06-25 2016-08-05 ホモ二量体タンパク質コンストラクト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016154365A Active JP6538622B2 (ja) 2010-06-25 2016-08-05 ホモ二量体タンパク質コンストラクト

Country Status (10)

Country Link
US (3) US10590195B2 (cg-RX-API-DMAC7.html)
EP (2) EP2585107B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013532971A (cg-RX-API-DMAC7.html)
KR (2) KR20130087517A (cg-RX-API-DMAC7.html)
CN (1) CN102985109B (cg-RX-API-DMAC7.html)
AU (1) AU2011268934B2 (cg-RX-API-DMAC7.html)
CA (1) CA2803058C (cg-RX-API-DMAC7.html)
DK (1) DK2585107T3 (cg-RX-API-DMAC7.html)
RU (1) RU2624041C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011161244A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1599504B1 (en) * 2003-02-25 2014-12-03 Vaccibody AS Modified antibody
JP2013532971A (ja) 2010-06-25 2013-08-22 バッシボディ アクスイェ セルスカプ ホモ二量体タンパク質コンストラクト
US9901635B2 (en) * 2011-12-21 2018-02-27 Vaccibody As Vaccines against HPV
CA3008437A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
KR102682118B1 (ko) 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
AU2017332452B2 (en) 2016-09-23 2021-01-07 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
WO2021204911A1 (en) * 2020-04-07 2021-10-14 Evaxion Biotech A/S Neoepitope immunotherapy with apc targeting unit
IL297621A (en) 2020-05-01 2022-12-01 Nykode Therapeutics ASA Betacoronavirus prophylaxis and therapy
EP4181949A1 (en) * 2020-07-14 2023-05-24 Evaxion Biotech A/S Apc targeting units for immunotherapy
IL305777A (en) 2021-03-26 2023-11-01 Nykode Therapeutics ASA Medical combination for cancer treatment
WO2022233851A1 (en) 2021-05-03 2022-11-10 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
WO2022238432A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunoinhibitory compounds
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
EP4337247A1 (en) 2021-05-10 2024-03-20 Nykode Therapeutics ASA Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders
WO2022238420A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunostimulatory compounds
WO2022238402A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Tolerance-inducing constructs and composition and their use for the treatment of immune disorders
WO2023079001A1 (en) 2021-11-03 2023-05-11 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2
EP4608436A1 (en) 2022-10-25 2025-09-03 Nykode Therapeutics ASA Constructs and their use
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5646016A (en) 1991-02-06 1997-07-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
WO1994008601A1 (en) 1992-10-14 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
EP0920522B1 (en) 1996-08-14 2003-10-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES A vector for polynucleotide vaccines
GB9820014D0 (en) 1998-09-14 1998-11-04 Cancer Res Campaign Tech Receptor antagonists and uses thereof
US20030125521A1 (en) 2001-06-20 2003-07-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003005992A1 (fr) 2001-07-13 2003-01-23 Nanocarrier Co., Ltd. Composition de lyophilisation de micelle polymere d'encapsulation de medicaments et procede de preparation associe
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
ES2283759T3 (es) 2002-01-18 2007-11-01 Pierre Fabre Medicament Anticuerpos anti-igf-ir y sus aplicaciones.
CN1617888A (zh) 2002-01-18 2005-05-18 伊诺维奥埃斯 用于肌内给药的双特异性抗体dna的构建
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
EP1599504B1 (en) * 2003-02-25 2014-12-03 Vaccibody AS Modified antibody
CA2519953C (en) * 2003-03-24 2016-01-05 The Scripps Research Institute Dna vaccine against tumor growth and methods of use thereof
WO2005052119A2 (en) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants of immune response
WO2010042654A2 (en) 2008-10-07 2010-04-15 The Regents Of The University Of California Recombinant nell protein production
UA94060C2 (ru) * 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
US20090010948A1 (en) * 2006-12-15 2009-01-08 The University Of Hong Kong Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10
WO2008080218A1 (en) * 2006-12-29 2008-07-10 Osprey Pharmaceuticals Usa, Inc. Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof
JP2013532971A (ja) 2010-06-25 2013-08-22 バッシボディ アクスイェ セルスカプ ホモ二量体タンパク質コンストラクト

Similar Documents

Publication Publication Date Title
JP2013532971A5 (cg-RX-API-DMAC7.html)
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
RU2013103335A (ru) Конструкции гомодимерных белков
Serradell et al. Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins
Raghuwanshi et al. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein
Zhang et al. Peptide-based nanovaccines in the treatment of cervical cancer: a review of recent advances
Fan et al. Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes
JP2017507117A5 (cg-RX-API-DMAC7.html)
JP2015529678A5 (cg-RX-API-DMAC7.html)
JP2015508284A5 (cg-RX-API-DMAC7.html)
JP2008541768A5 (cg-RX-API-DMAC7.html)
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
ES2775278T3 (es) Composición formada por un antígeno ligado a un ligando de la superfamilia TNF
HRP20220924T1 (hr) Imunoterapija zasnovana na pd-l1
JP2015509707A5 (cg-RX-API-DMAC7.html)
JP2012509071A5 (cg-RX-API-DMAC7.html)
JP2016516723A5 (cg-RX-API-DMAC7.html)
Gupta et al. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases
CN104039833A (zh) 针对hpv的疫苗
CA2831294A1 (en) Compositions and methods to immunize against hepatitis c virus
CN105143251B (zh) 流感核蛋白疫苗
AU2021307553A1 (en) APC targeting units for immunotherapy
Kawai et al. Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses
Gonzalez-Valdivieso et al. A DNA vaccine delivery platform based on elastin-like recombinamer nanosystems for rift valley fever virus
US20250099575A1 (en) Mrna vaccine